Clinical Report: Nomogram for Predicting RAI Response in Thyroid Cancer

Overview

This study developed and validated a nomogram to predict treatment response to initial radioactive iodine therapy (RAI) in patients with intermediate- or high-risk differentiated thyroid cancer (DTC) based on serum cytokine levels and thyroglobulin measurements. Key predictors identified include serum thyroglobulin and interferon-alpha.

Background

Differentiated thyroid cancer (DTC) is the most prevalent form of thyroid cancer, and its management often includes radioactive iodine therapy (RAI) to eliminate residual disease. Accurate prediction of treatment response is crucial for optimizing patient management and follow-up strategies, particularly for those at intermediate or high risk of recurrence. This study addresses the gap in predictive modeling by integrating serum cytokine levels with traditional biomarkers.

Data Highlights

Key Findings

• Serum thyroglobulin (sTg) and serum interferon-alpha (IFN-α) were identified as independent predictors of treatment response.
• The nomogram model showed acceptable predictive performance in the training cohort.
• Calibration curves indicated a high degree of concordance between predicted probabilities and observed outcomes.
• External validation confirmed the model's clinical utility.
• Patients were categorized into excellent response (ER) and non-excellent response (non-ER) groups based on the 2025 ATA Response Evaluation System.

Clinical Implications

The nomogram developed in this study can assist clinicians in predicting treatment responses to RAI therapy, enabling more personalized follow-up and management strategies for patients with intermediate- or high-risk DTC. Early identification of patients likely to have poor responses may optimize treatment planning.

Conclusion

This study successfully developed and validated a nomogram integrating serum cytokine levels and thyroglobulin measurements, providing a valuable tool for predicting treatment response in DTC patients undergoing initial RAI therapy.

Related Resources & Content

1. 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
2. Thyroglobulin Thresholds for Monitoring Low- and Intermediate-risk Thyroid Cancer: Insights from ITCO Real-world Data Analysis
3. T Lymphocytes Within Tumors Identify Thyroid-specific Antigens and Neoantigens in Thyroid Cancers Originating from Follicular Cells
4. Frontiers in Oncology — Development and validation of a pre-chemotherapy nomogram integrating systemic immune-inflammation index and prognostic nutritional index to predict severe adjuvant toxicity in colorectal cancer
5. European Radiology — Creation and assessment of a radiomics nomogram utilizing [18F]FDG PET/CT to forecast prognostic risks in patients with pretreatment diffuse large B cell lymphoma
6. 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer
7. Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer | New England Journal of Medicine
8. Frontiers | Development of a predictive nomogram for intermediate-risk differentiated thyroid cancer patients after fixed 3.7GBq (100mCi) radioiodine remnant ablation
9. Frontiers | Stimulated thyroglobulin and pre-ablation antithyroglobulin antibody products can predict the response to radioiodine therapy of TgAb-positive differentiated thyroid cancer patients: a retrospective study
10. Systemic Immune-Inflammation Index and Systemic Inflammation Response Index Predict the Response to Radioiodine Therapy for Differentiated Thyroid Cancer - PMC
11. Nomogram models for predicting outcomes in thyroid cancer patients with distant metastasis receiving 131iodine therapy | Scientific Reports